Medibank (ASX:MPL) share price lifts as staff vaccine mandate hits headlines

Here's the latest news from Medibank Private.

The Medibank Private Ltd (ASX: MPL) share price is in the green today amid news the company will soon require nearly all its staff to be vaccinated against COVID-19.

Previously, only Medibank's front-line employees had to be vaccinated against COVID-19.

Medibank released the potentially divisive announcement yesterday and many media outlets reported on the changes after the ASX closed.

At the time of writing, the Medibank share price is $3.55, 0.85% higher than its previous close.

That's relatively in line with the broader market's performance this morning. Right now, the S&P/ASX 200 Index (ASX: XJO) has gained 0.2%. Meanwhile, the All Ordinaries Index (ASX: XAO) is up 0.3%.

Let's take a closer look at the latest news from Medibank.

man receiving covid 19 vaccine moderna biontech

Image source: Getty Images

Medibank extends employee vaccine mandate

The Medibank share price is gaining today amid headlines most of its staff are facing vaccination deadlines.

It follows fellow ASX-listed companies Crown Resorts Ltd (ASX: CWN) and Qantas Airways Limited's (ASX: QAN) decisions to do the same. Qantas declared all its staff must have a COVID-19 vaccination in August, while Crown mandated vaccination for employees last month.

Employees working in Medibank's retail or offices will soon need to be at least partially inoculated against COVID-19 to attend their workplaces or work events.

Those working in Medibank's retail segment must have had 2 doses of a COVID-19 vaccine by 15 December. All other employees face a deadline of 31 January 2022.  

Additionally, its executive leadership team and board of directors will be fully inoculated against COVID-19 by mid-October.

Employees who work completely from home are exempt from the mandate, as are those who can't get vaccinated for medical reasons.

Previously, Medibank required its frontline health workers to have at least one jab by 1 November, while those working in residential aged care had to have had their first dose by mid-September.

Commentary from management

Medibank's CEO David Koczka commented on the company's new vaccine mandate, saying:

As a company with more than 1,400 health professionals and a broader team focused on health and wellbeing each day, there is widespread understanding of the benefits of COVID vaccination across our business…

We've made this decision to help keep our people and customers safe and to support the immense effort of the nation's healthcare workers.

Medibank share price snapshot

The Medibank share price has been performing well on the ASX lately.

It has gained 16.6% since the start of 2021. It is also 36.8% higher than it was this time last year.

Motley Fool contributor Brooke Cooper has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Healthcare Shares

Two colleagues looking at a graph and comparing share prices.
Healthcare Shares

Telix vs Clinuvel Pharmaceuticals: Which ASX healthcare share deserves your next $1,000 of investment capital?

We compare Telix and Clinuvel Pharmaceuticals on valuation, dividends, and momentum—which ASX healthcare stock looks more compelling now?

Read more »

Numerous Australian dollar notes laid out.
Healthcare Shares

I'd buy 6,462 shares of this ASX stock to aim for $200 a month of passive income

This business can provide very healthy dividends.

Read more »

A doctor appears shocked as he looks through binoculars on a blue background.
Healthcare Shares

UBS thinks Telix Pharmaceuticals shares will go how high?

Good news out of the US has led to a share price target upgrade.

Read more »

Scientist taking down notes from a tablet, with two other scientists working in the background.
Healthcare Shares

Healius vs Australian Clinical Labs: Which ASX pathology share wins?

Healius and Australian Clinical Labs are both top pathology providers, but one stands out for profits, dividends, and recent momentum.

Read more »

Doctor looks at a graph on a tablet.
Healthcare Shares

Ramsay Health Care vs Sonic Healthcare: Which healthcare stock is better value?

Which offers better value — Ramsay Health Care or Sonic Healthcare? I compare their fundamentals, dividends, momentum and reveal my…

Read more »

A doctor looks unsure.
Healthcare Shares

CSL shares jump 93%: Is the ASX biotech stock a buy, sell or hold for October?

Can the CSL share price rebound keep going?

Read more »

Two doctors having a discussion about a patient diagnosis, holding digital tablet.
Healthcare Shares

Are CSL shares a buy after its big news?

I look at what CSL’s latest drug development deal could mean for the healthcare giant’s long-term growth.

Read more »

A female scientist in a laboratory setting using a tablet to review data, with a male scientist working in the background.
Healthcare Shares

ResMed vs Fisher & Paykel Healthcare: Which is better value?

How do ResMed and Fisher & Paykel compare on value, income, and share price momentum? Here’s my verdict on which…

Read more »